v3.25.1
SEGMENT REPORTING - Revenue (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
USD ($)
brand
segment
reportingUnit
productFamily
Mar. 31, 2024
USD ($)
Segment reporting    
Number of operating segments | segment 2  
Established brand products | brand 16  
Product families | productFamily 100  
Net Revenues $ 197,122 $ 137,430
Cost of sales (excluding depreciation and amortization) 73,037 49,157
Research and development expense 10,564 10,511
Selling, general, and administrative 76,528 48,021
Depreciation and amortization 22,891 14,686
Contingent consideration fair value adjustment (12,092) 90
Gain on sale of building 0 (5,347)
Operating income 26,194 20,312
Unrealized loss on investment in equity securities (921) 9,655
Interest expense, net (5,484) (4,600)
Other income (expense), net 198 (32)
Income Before Income Tax Expense $ 19,987 25,335
Number of reporting units | segment 3  
Rare Disease and Brands    
Segment reporting    
Number of reporting units | reportingUnit 2  
Operating Segments | Generics and Other    
Segment reporting    
Net Revenues $ 103,040 74,814
Cost of sales (excluding depreciation and amortization) 46,501 36,800
Research and development expense 6,588 8,019
Selling, general, and administrative 1,408 1,010
Depreciation and amortization 0 0
Contingent consideration fair value adjustment 0 0
Gain on sale of building   0
Operating income 48,543 28,985
Unrealized loss on investment in equity securities 0 0
Interest expense, net 0 0
Other income (expense), net 0 0
Income Before Income Tax Expense 48,543 28,985
Operating Segments | Rare Disease and Brands    
Segment reporting    
Net Revenues 94,082 62,616
Cost of sales (excluding depreciation and amortization) 26,536 12,357
Research and development expense 3,976 2,492
Selling, general, and administrative 42,436 24,666
Depreciation and amortization 0 0
Contingent consideration fair value adjustment 0 0
Gain on sale of building   0
Operating income 21,134 23,101
Unrealized loss on investment in equity securities 0 0
Interest expense, net 0 0
Other income (expense), net 0 0
Income Before Income Tax Expense 21,134 23,101
Corporate and Unallocated    
Segment reporting    
Net Revenues 0 0
Cost of sales (excluding depreciation and amortization) 0 0
Research and development expense 0 0
Selling, general, and administrative 32,684 22,345
Depreciation and amortization 22,891 14,686
Contingent consideration fair value adjustment (12,092) 90
Gain on sale of building   (5,347)
Operating income (43,483) (31,774)
Unrealized loss on investment in equity securities (921) 9,655
Interest expense, net (5,484) (4,600)
Other income (expense), net 198 (32)
Income Before Income Tax Expense $ (49,690) $ (26,751)